Gordon David N. 4
4 · Aclaris Therapeutics, Inc. · Filed Jul 7, 2021
Insider Transaction Report
Form 4
Gordon David N.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-07-02+6,000→ 150,078 total - Exercise/Conversion
Restricted Stock Units
2021-07-02−6,000→ 6,000 total→ Common Stock (6,000 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date.